Free Trial
NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

Zoetis logo
$156.15 +6.28 (+4.19%)
Closing price 05/7/2025 03:59 PM Eastern
Extended Trading
$155.12 -1.04 (-0.66%)
As of 05/7/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Zoetis Stock (NYSE:ZTS)

Key Stats

Today's Range
$151.01
$156.62
50-Day Range
$144.09
$171.70
52-Week Range
$139.70
$200.33
Volume
4.45 million shs
Average Volume
2.48 million shs
Market Capitalization
$69.67 billion
P/E Ratio
28.55
Dividend Yield
1.28%
Price Target
$212.13
Consensus Rating
Buy

Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

ZTS MarketRank™: 

Zoetis scored higher than 97% of companies evaluated by MarketBeat, and ranked 84th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zoetis has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Zoetis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Zoetis' stock forecast and price target.
  • Earnings Growth

    Earnings for Zoetis are expected to grow by 11.20% in the coming year, from $6.07 to $6.75 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zoetis is 28.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.08.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zoetis is 28.55, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.88.

  • Price to Earnings Growth Ratio

    Zoetis has a PEG Ratio of 2.78. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Zoetis has a P/B Ratio of 14.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.74% of the float of Zoetis has been sold short.
  • Short Interest Ratio / Days to Cover

    Zoetis has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Zoetis has recently increased by 12.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Zoetis pays a meaningful dividend of 1.28%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Zoetis has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Zoetis is 36.56%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Zoetis will have a dividend payout ratio of 29.63% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

  • Read more about Zoetis' dividend.
  • Percentage of Shares Shorted

    1.74% of the float of Zoetis has been sold short.
  • Short Interest Ratio / Days to Cover

    Zoetis has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Zoetis has recently increased by 12.17%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Zoetis has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 52 news articles for Zoetis this week, compared to 22 articles on an average week.
  • Search Interest

    15 people have searched for ZTS on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.
  • MarketBeat Follows

    14 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zoetis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $312,254.00 in company stock.

  • Percentage Held by Insiders

    Only 0.16% of the stock of Zoetis is held by insiders.

  • Percentage Held by Institutions

    92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zoetis' insider trading history.
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Zoetis (ZTS) Delivers Strong Q1 2025 Performance
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
See More Headlines

ZTS Stock Analysis - Frequently Asked Questions

Zoetis' stock was trading at $162.93 at the start of the year. Since then, ZTS stock has decreased by 4.2% and is now trading at $156.15.
View the best growth stocks for 2025 here
.

Zoetis Inc. (NYSE:ZTS) issued its quarterly earnings results on Tuesday, May, 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company's revenue was up 1.4% on a year-over-year basis.

Zoetis subsidiaries include Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and more.

Zoetis' top institutional shareholders include Bank of New York Mellon Corp (1.19%), Brown Advisory Inc. (0.99%), Pictet Asset Management Holding SA (0.60%) and Banque Pictet & Cie SA (0.59%). Insiders that own company stock include Kristin C Peck, Heidi C Chen, Roxanne Lagano, Willie M Reed and Robert J Polzer.
View institutional ownership trends
.

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Record date for 3/4 Dividend
1/21/2025
Ex-Dividend for 3/4 Dividend
1/21/2025
Dividend Payable
3/04/2025
Record date for 6/3 Dividend
4/21/2025
Ex-Dividend for 6/3 Dividend
4/21/2025
Last Earnings
5/06/2025
Today
5/07/2025
Dividend Payable
6/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:ZTS
Employees
13,800
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$213.56
High Stock Price Target
$244.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+36.8%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
28.55
Forward P/E Ratio
25.72
P/E Growth
2.78
Net Income
$2.49 billion
Pretax Margin
33.85%

Debt

Sales & Book Value

Annual Sales
$9.26 billion
Cash Flow
$7.01 per share
Price / Cash Flow
22.26
Book Value
$10.65 per share
Price / Book
14.66

Miscellaneous

Free Float
447,076,000
Market Cap
$69.67 billion
Optionable
Optionable
Beta
0.94

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:ZTS) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners